It’s notable that in President Obama’s recent, first speech before Congress, the only disease mentioned in addressing the country’s urgent need for health care reform was cancer. Obama pledged “to seek a cure for cancer in our time,” a tall order that has so far eluded researchers.
Each cancer drug approval and every trial represents yet another step towards achieving that elusive goal. Yet we were reminded again of the risks associated with cancer drug development last week with the negative outcome of the Phase 3 study evaluating elesclomol [Synta, GSK] in melanoma. With that in mind, we wanted to pique your interest in looking at OBR’s RADAR, just updated, to see what’s on the horizon in 1H09 for oncology drugs in the way of pending FDA decisions and anticipated key clinical trial data:
Pivotal Phase 3 results due:
Upcoming PDUFA action dates:
OBR Radar was developed to keep our reading audience ahead of market moving events in oncology. For more information and the latest updates, go to http://www.obroncology.com/radar.php or just click on the RADAR icon in any edition of OBR daily.
You must be logged in to post a comment